Skip to Content
Merck
  • Molecular mechanism of the inhibition of TDP-43 amyloidogenesis by QBP1.

Molecular mechanism of the inhibition of TDP-43 amyloidogenesis by QBP1.

Archives of biochemistry and biophysics (2019-10-01)
Miguel Mompeán, Daniel Ramírez de Mingo, Rubén Hervás, María Del Carmen Fernández-Ramírez, Mariano Carrión-Vázquez, Douglas V Laurents
ABSTRACT

Transactive Response DNA-Binding Protein of 43 kDa (TDP-43) is an essential human protein implicated in Amyotrophic Lateral Sclerosis (ALS) and common dementias. Its C-terminal disordered region, composed of residues 264-414 includes a hydrophobic segment (residues 320-340), which drives physiological liquid/liquid phase separation and a Q/N-rich segment (residues 341-357), which is essential for pathological amyloid formation. Due to TDP-43's relevance for pathology, identifying inhibitors and characterizing their mechanism of action are important pharmacological goals. The Polyglutamine Binding Peptide 1 (QBP1), whose minimal active core is the octapeptide WGWWPGIF, strongly inhibits the aggregation of polyQ-containing amyloidogenic proteins such as Huntingtin. Rather promiscuous, this inhibitor also blocks the aggregation of other glutamine containing amyloidogenic proteins, but not Aβ, and its mechanism of action remains unknown. Using a series of spectroscopic assays and biochemical tests, we establish that QBP1 binds and inhibits amyloid formation by TDP-43's Q/N-rich region. NMR spectroscopic data evince that the aromatic rings of QBP1 accept hydrogen bonds from the HN groups of the Asn and Gln to block amyloidogenesis. This mechanism of blockage may be general to polyphenol amyloid inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
QBP1, ≥95% (HPLC)